

CD19

Research Grade Loncastuximab

| | | | |
|---------------------------------|---|------------------|------------------|
| Catalog No. | DHD10806A DHD10806B | Quantity: | 100 µg 1.0 mg |
| Alternate Names: | B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12 | | |
| Description: | Loncastuximab is a chimeric monoclonal antibody directed against B-lymphocyte antigen CD19. It is approved for the treatment of diffuse large B-cell lymphoma (DLBCL), when conjugated to a valine-alanine cleavable cytotoxic pyrrolobenzodiazepine (PBD) dimer. | | |
| UniProt ID (target): | P15391 | | |
| Specificity: | Human B-lymphocyte antigen CD19 | | |
| Concentration: | 1.0 mg/ml, lot specific | | |
| Source: | Mammalian cell line | | |
| Isotype: | Chimeric IgG1 kappa | | |
| Formulation: | PBS buffer, pH 7.5 | | |
| Purity: | > 95% by SDS-PAGE | | |
| Endotoxin Level: | ≤ 0.01 EU/µg by LAL analysis | | |
| Purification: | Protein A/G affinity chromatography | | |
| Applications: | Functional studies | | |
| INN: | Loncastuximab | | |
| Storage & Stability: | Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences[®]
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com